Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma

by Plummer, R, Lorigan, P, Brown, E, Zaucha, R, Moiseyenko, V, Demidov, L, Soriano, V, Chmielowska, E, Andrés, R, Kudryavtseva, G, Kahatt, C, Szyldergemajn, S, Extremera, S, de Miguel, B, Cullell-Young, M, Calvert, H
Published 2013

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer

by Michaelson, M. D., Bellmunt, J., Hudes, G. R., Goel, S., Lee, R. J., Kantoff, P. W., Stein, C. A., Lardelli, P., Pardos, I., Kahatt, C., Nieto, A., Cullell-Young, M., Lewis, N. L., Smith, M. R.
Published 2012

Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study

by Calvo, E., Moreno, V., Flynn, M., Holgado, E., Olmedo, M. E., Lopez Criado, M. P., Kahatt, C., Lopez-Vilariño, J. A., Siguero, M., Fernandez-Teruel, C., Cullell-Young, M., Soto Matos-Pita, A., Forster, M.
Published in Ann Oncol (2017)